l-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations
Swita R. Singh
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska
Search for more papers by this authorSamantha T. Carreiro
Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorJessie Chu
Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorGanesh Prasanna
Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorMichael R. Niesman
Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorWalter W. Collette III
Department of Drug Safety R&D, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorHusam S. Younis
Department of Drug Safety R&D, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorSoisurin Sartnurak
Research Science & Technology - Formulations, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorCorresponding Author
Hovhannes J. Gukasyan
Research Science & Technology - Formulations, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, USA
1Pfizer Global R&D, La Jolla Laboratories, 10777 Science Center Drive, CB1-1320, San Diego, CA 92121 USA. E-mail: [email protected]Search for more papers by this authorSwita R. Singh
Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska
Search for more papers by this authorSamantha T. Carreiro
Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorJessie Chu
Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorGanesh Prasanna
Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorMichael R. Niesman
Department of Ocular Biology, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorWalter W. Collette III
Department of Drug Safety R&D, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorHusam S. Younis
Department of Drug Safety R&D, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorSoisurin Sartnurak
Research Science & Technology - Formulations, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, USA
Search for more papers by this authorCorresponding Author
Hovhannes J. Gukasyan
Research Science & Technology - Formulations, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, USA
1Pfizer Global R&D, La Jolla Laboratories, 10777 Science Center Drive, CB1-1320, San Diego, CA 92121 USA. E-mail: [email protected]Search for more papers by this authorAbstract
Objectives The use of L-carnosine as an excipient in topical ophthalmic formulations containing gellan gum, a carbohydrate polymer with in-situ gelling properties upon mixing with mammalian tear fluid, was developed as a novel platform to extend precorneal duration. Specific utilisation of L-carnosine as a buffer in gellan gum carrying vehicles was characterised.
Methods Buffer capacity was evaluated using 7.5, 13.3, and 44.2 mM L-carnosine in a pH range of 5.5–7.5. Accelerated chemical stability was determined by HPLC at L-carnosine concentrations of 5–100 mM. Combinations of 7.5 mM L-carnosine with 0.06–0.6% (w/v) gellan gum were characterised rheologically. L-Carnosine-buffered solutions of gellan gum were tested for acute topical ocular tolerance in vivo in pigmented rabbits. A unique formulation combining timolol (which lowers intraocular pressure) in L-carnosine-buffered gellan gum was compared with Timoptic-XE in normotensive dogs.
Key findings L-Carnosine exhibited optimal pharmaceutical characteristics for use as a buffer in chronically administered topical ocular formulations. Enhancement trends were observed in solution-to-gel transition of L-carnosine-buffered vehicles containing gellan gum vs comparators. Topical tolerability of L-carnosine-buffered gellan gum formulations and lowering of intraocular pressure were equivalent with timolol and Timoptic-XE.
Conclusions Functional synergy between excipients in gellan gum formulations buffered with L-carnosine has potential for topical ocular dosage forms with sustained precorneal residence.
References
- 1 Lee VH, Robinson JR. Topical ocular drug delivery: recent developments and future challenges. J Ocul Pharmacol 1986; 2: 67–108.
- 2 Rozier A. et al. Gelrite®: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm 1989; 57: 163–168.
- 3 El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int J Pharm 2002; 241: 47–55.
- 4 Ludwig A.. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005; 57: 1595–1639.
- 5 Gunning FP et al. Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study. Graefes Arch Clin Exp Ophthalmol 1993; 231: 384–388.
- 6 Carlfors J. et al. Rheological evaluation of Gelrite in situ gels for ophthalmic use. Eur J Pharm Sci 1998; 6: 113–119.
- 7 Balasubramaniam J. et al. In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for indomethacin. Acta Pharm 2003; 53: 251–261.
- 8 Balasubramaniam J., Pandit JK. Ion-activated in situ gelling systems for sustained ophthalmic delivery of ciprofloxacin hydrochloride. Drug Deliv 2003; 10: 185–191.
- 9 El-Kamel A. et al. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv 2006; 13: 55–59.
- 10 Sultana Y. et al. Ion-activated, Gelrite-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv 2006; 13: 215–219.
- 11 Kanesaka S. et al. Binding effect of Cu(2+) as a trigger on the sol-to-gel and the coil-to-helix transition processes of polysaccharide, gellan gum. Biomacromolecules 2004; 5: 863–868.
- 12 Mazuel C. Friteyre M-C 1989 Ophthalmological composition of the type which undergoes liquid-gel phase transition, in (USPTO#4861760 ed), Merck & Co., Inc., USA.
- 13 O'Neil MJ. The Merck Index: an encyclopedia of chemicals, drugs, and biologicals, 14th edn. Merck Manuals, Whitehouse Station, NJ, USA, 2006.
- 14 Gulevitch V., Amiradgibi S.. Uber das carnosine, eine neue organische base des fleischextraktes. Ber Deutsch Chem Gesellschaft 1900; 33: 15504–15509.
- 15 Babizhayev MA et al. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D 2004; 5: 125–139.
- 16 Babizhayev MA et al. l-Carnosine (beta-alanyl-l-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities. Biochem J 1994; 304(Pt 2): 509–516.
- 17 Babizhayev MA et al. N alpha-acetylcarnosine is a prodrug of l-carnosine in ophthalmic application as antioxidant. Clin Chim Acta 1996; 254: 1–21.
- 18 Babizhayev MA et al. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001; 22: 979–994.
- 19 Babizhayev MA. Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention. Drugs R D 2005; 6: 345–345.
- 20 Babizhayev MA. Kasus-Jacobi A State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases. Curr Clin Pharmacol 2009; 4: 4–37.
- 21 Matsukura T., Tanaka H.. Applicability of zinc complex of l-carnosine for medical use. Biochemistry (Mosc) 2000; 65: 817–817.
- 22 Paulsson M. et al. Rheological studies of the gelation of deacetylated gellan gum (Gelrite) in physiological conditions. Eur J Pharm Sci 1999; 9: 99–105.
- 23 Bachman WG, Wilson G. Essential ions for maintenance of the corneal epithelial surface. Invest Ophthalmol Vis Sci 1985; 26: 1484–1488.
- 24 Van Slyke DD. On the measurement of buffer values and on the relationship of buffer value to the dissociation constant of the buffer and the concentration and reaction of the buffer solution. J Biol Chem 1922; 52: 525–525.
- 25 Milas M. et al. On the physicochemical properties of gellan gum. Biopolymers 1990; 30: 451–464.
- 26 Takiyama N. et al. The effects of a timolol maleate gel-forming solution on normotensive beagle dogs. J Vet Med Sci 2006; 68: 631–633.
- 27 Patton TF, Robinson JR. Influence of topical anesthesia on tear dynamics and ocular drug bioavailability in albino rabbits. J Pharm Sci 1975; 64: 267–267.
- 28 Conrad JM et al. Influence of tonicity and pH on lacrimation and ocular drug bioavailability. J Parenter Drug Assoc 1978; 32: 149–161.
- 29 Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability i: evaluation of fluorometholone. J Pharm Sci 1975; 64: 931–936.
- 30 Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability II: evaluation of pilocarpine. J Pharm Sci 1977; 66: 1222–1228.
- 31 Patton TF, Robinson JR. Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J Pharm Sci 1975; 64: 1312–1316.
- 32 Gennaro AR, Remington JP. Remington: the science and practice of pharmacy. In:. G. Hecht Ophthalmic Preparations Easton, PA, USA Mack Pub. Co., 1995 page V.
- 33 Babizhayev MA et al. The natural histidine-containing dipeptide Nalpha-acetylcarnosine as an antioxidant for ophthalmic use. Biochemistry (Mosc) 2000; 65: 588–598.
- 34 Harris DC. Quantitative Chemical Analysis. New York: WH Freeman and Co, 2007.
- 35 Zenisek A., Kral JA. The occurrence of urocanic acid in human sweat. Biochim Biophys Acta 1953; 12: 479–480.
- 36 Bergfeld WF et al. Safety of ingredients used in cosmetics. J Am Acad Dermatol 2005; 52: 125–132.
- 37 Babizhayev MA, Meguro K. Combined use of carnosinase inhibitor with l-carnosines and composition, in (USPTO application# US2006116328 A1), Innovative Vision Products Inc., USA, Hamari Chemicals Ltd, JP. 2005.
- 38 Meseguer G. et al. Gamma scintigraphic comparison of eyedrops containing pilocarpine in healthy volunteers. J Ocul Pharmacol Ther 1996; 12: 481–488.
- 39 Kador PF et al. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther 2007; 23: 116–123.
- 40 Marra M. et al. 2nd ophthalmic drug development and delivery summit. Expert Opin Drug Deliv 2007; 4: 77–85.
- 41 Greaves JL et al. Scintigraphic assessment of an ophthalmic gelling vehicle in man and rabbit. Curr Eye Res 1990; 9: 415–420.
- 42 Hincu LL et al. Studies regarding preparation and evaluation from ophthalmic therapeutic system of in situ gel forming systems with piroxicam. Farmacia (Bucharest, Romania) 2007; 55: 557–568.
- 43 Kalam M. et al. Gelrite-based in vitro gelation ophthalmic drug delivery system of gatifloxacin. J Dispers Sci Technol 2008; 29: 89–96.
- 44 Podder SK et al. Improving the safety of topically applied timolol in the pigmented rabbit through manipulation of formulation composition. Exp Eye Res 1992; 54: 747–757.
- 45 Svec AL, Strosberg AM. Therapeutic and systemic side effects of ocular beta-adrenergic antagonists in anesthetized dogs. Invest Ophthalmol Vis Sci 1986; 27: 401–405.
- 46 Gelatt KN et al. Evaluation of multiple doses of 4 and 6% timolol, and timolol combined with 2% pilocarpine in clinically normal beagles and beagles with glaucoma. Am J Vet Res 1995; 56: 1325–1331.
- 47 Bucolo C. et al. Pharmacological evaluation of a new timolol/pilocarpine formulation. Ophthalmic Res 1998; 30: 101–106.
- 48 Ermakova VN et al. Effect of carnosine on intraocular pressure. Biull Eksp Biol Med 1988; 105: 451–453.
- 49 Basu SK et al. Proton-driven dipeptide uptake in primary cultured rabbit conjunctival epithelial cells. Invest Ophthalmol Vis Sci 1998; 39: 2365–2373.
- 50 Yang JJ et al. Meeting future challenges in topical ocular drug delivery: development of an air-interfaced primary culture of rabbit conjunctival epithelial cells on a permeable support for drug transport studies. J Control Release 2000; 65: 1–11.
- 51 Hosoya K. et al. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm 2005; 60: 227–240.